CBA
ALNY icon

Coastal Bridge Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Coastal Bridge Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$327K Sell
987
-61
-6% -$20.8K 0.02% 367
2025
Q4 		$417K Sell
1,048
-49
-4% -$21.7K 0.03% 328
2025
Q3 		$500K Buy
1,097
+25
+2% +$10.2K 0.04% 296
2025
Q2 		$350K Sell
1,072
-64
-6% -$17.7K 0.03% 335
2025
Q1 		$307K Buy
+1,136
New +$292K 0.08% 192

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coastal Bridge Advisors's ALNY Position: Q1 2026 in Review

Coastal Bridge Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.8% in Q1 2026, selling an estimated $20.8K and leaving 987 shares worth $327K. The position accounts for 0.02% of the portfolio, ranked #367.

Coastal Bridge Advisors first reported a position in ALNY in Q1 2025 and has held it in 5 quarters since. The position peaked at $500K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Coastal Bridge Advisors held 987 shares of Alnylam Pharmaceuticals worth $327K as of Q1 2026.
  • Coastal Bridge Advisors sold 61 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $20.8K.
  • Alnylam Pharmaceuticals made up 0.02% of Coastal Bridge Advisors's portfolio in Q1 2026, its #367 holding.
  • Coastal Bridge Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Coastal Bridge Advisors's Alnylam Pharmaceuticals position peaked at $500K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Coastal Bridge Advisors's 13F filing for Q1 2026, filed 14 May 2026.